Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients ...

Cogent Biosciences Inc. (NASDAQ:COGT) surged 12.6% in Monday’s premarket session after unveiling encouraging top-line ...

MaaT013 showed a 62% GI overall response rate at day 28, significantly exceeding historical controls, with durable responses and survival benefits for responders. Safety profile was acceptable, with ...

Treatment with Zervyteg (MaaT013) generated encouraging results and demonstrated an acceptable safety profile in patients with acute graft-vs-host disease that affects the gastrointestinal tract and ...

Research presented at the 2025 ASH Annual Meeting sheds light on serious side effects that appear weeks or months after CAR T cell therapy for multiple myeloma.

Balance training patients may soon be able to get AI feedback during home exercises, with four wearable sensors and a new ...

We are experiencing a new renaissance…of psychedelic medicine.” By Leah Romero, Source NM New Mexico Department of Health ...

Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably ...

In October 2025, Karolinska Institutet launched a brand-new two-week course giving PhD students a unique insight into how ...

Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, ...

In this interview, George Eastwood, executive director of the Emily Whitehead Foundation and CAR T Vision steering committee member discusses barriers and strategies for expanding access to CAR T-cell ...

Like Marwan, the country is struggling to heal a year after the Assad dynasty’s repressive 50-year reign came to an end following 14 years of civil war that left an estimated half a million people ...